VXRT:OTCMKTS
Vaxart Inc
$0,76
arrow_downward
-1,59%(-0,012) 1G
4 May, 16:00:00 GMT-4 · USD
search
Tüm semboller
1G
5G
1A
6A
Yıl Başından Beri
1Y
5Y
MAKS
| Sembol | Fiyat | Değişiklik | Değişiklik % |
|---|
insights_autoVXRT ile ilgili en önemli analizler oluşturuluyor...
Açık
$0,76
Yüksek
$0,79
Düşük
$0,75
Piy. değ.
182,34 Mn
İşlem Hacmi
392,82 B
F/K oranı
10,69
52 haftalık en yüksek
$0,79
52 haftalık en düşük
$0,75
HBK
$0,07
Beta
1,18
Tedavüldeki hisse senedi sayısı
241,41 Mn
Çalışan sayısı
65
Haberler
Web genelindeki kaynaklardan
Stock Titan
·
3 gün önce
Vaxart (VXRT) director James B. Breitmeyer files initial Form 3 with no trades
Profil
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
Vaxart Inc hakkında
CEO-
Çalışan Sayısı65
Kuruluş TarihiMar 2004
Genel MerkezSouth San Francisco, Kaliforniya, Amerika Birleşik Devletleri
Sektör-
Web Sitesivaxart.com
Yapay zeka içeriklerinde hata olabilir. Daha fazla bilgi